Puretech Health Stock Price, News & Analysis

PureTech Health plc has announced the initiation of a clinical study for LYT-100 (deupirfenidone), a potential treatment for idiopathic pulmonary fibrosis (IPF). This global, randomized study aims to assess the efficacy and tolerability of LYT-100 compared to pirfenidone and a placebo. Approximately 240 patients will participate, with topline results expected by the end of 2023. Additionally, the company is advancing its LYT-200 program for solid tumors, with plans to initiate a leukemia study by year-end 2022.

PureTech Health plc has announced the opening of a new large-scale CGMP facility by its Founded Entity, Vedanta Biosciences, to manufacture clinical and commercial supplies for its microbiome therapies. This facility will support the planned Phase 3 clinical trial and potential commercial launch of VE303, targeted at high-risk Clostridioides difficile infection. With established capabilities to produce defined bacterial consortia in compliance with global standards, Vedanta aims to enhance its leadership in microbiome-based therapies.

Vedanta Biosciences announces the opening of a new multi-product CGMP facility in Cambridge, MA, designed to manufacture oral therapies based on defined bacterial consortia. This facility will support the planned Phase 3 clinical trial and potential commercial launch of VE303 for Clostridioides difficile infection. The facility enhances Vedanta's manufacturing capabilities, ensuring compliance with global regulatory standards and addressing critical production challenges for microbiome-based therapies.

On June 15, 2022, PureTech Health held its Annual General Meeting, where shareholders approved all proposed resolutions. Notable outcomes include 100% approval for the Annual Report and Accounts, and the election of several directors. The vote breakdown for director elections showed high support, with the lowest approval at 95.99%. Shareholders also reappointed KPMG as auditors with 97.82% support and authorized the allotment of shares with 97.90% approval. Overall, the meeting reinforced shareholder confidence in the company's leadership and governance.

PureTech Health announced successful proof-of-principle for its LYT-300, an oral prodrug of allopregnanolone, achieving systemic blood levels approximately nine-fold greater than traditional oral allopregnanolone. This breakthrough is crucial as it aims to deliver the proven efficacy of allopregnanolone via simple oral dosing, overcoming limitations of intravenous delivery. The results validate PureTech's Glyph™ technology platform, designed to enhance oral bioavailability and lymphatic targeting, potentially impacting treatment for various neurological conditions, including postpartum depression.

PureTech Health announced results from a Phase 2 study of LYT-100 (deupirfenidone) in patients with post-acute “Long” COVID, revealing no treatment effect. However, the study reaffirmed LYT-100's strong safety and tolerability profile. PureTech will not pursue further studies in this patient population but will focus on initiating registration-enabling studies for LYT-100 in idiopathic pulmonary fibrosis (IPF) later this month, leveraging previously established efficacy of pirfenidone. The study involved 177 patients and showed meaningful improvements in walking distance for both treatment and placebo groups.

Vedanta Biosciences, a clinical-stage company, announced that CEO Bernat Olle will speak at the JMP Securities Life Sciences Conference on June 16, 2022, at 11:30 a.m. ET in New York. The company focuses on developing a new category of oral therapies based on defined bacterial consortia from the human microbiome to treat conditions such as C. difficile infection and inflammatory bowel diseases. Vedanta controls a significant patent portfolio and boasts expertise in bacterial consortium design, with a belief in their pioneering research in this emerging field.

PureTech Health plc announced that Matt Franklin will join Akili Interactive Labs as President and Chief Operating Officer on June 21, 2022. Franklin, a life sciences expert with over 20 years of experience, has previously held significant roles at Exact Sciences, Thrive Earlier Detection Corp, and Foundation Medicine. His appointment aims to drive Akili's growth and prepare for the commercialization of its cognitive treatment product, EndeavorRx®, focusing on enhancing operational efficiency and strategic marketing.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) announced participation in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 AM EDT in New York City. Presenters include Bharatt Chowrira, Ph.D., J.D., and Julie Krop, M.D. The discussion will cover the company’s innovative approaches to treating serious diseases, supported by a robust pipeline of 27 therapeutic candidates. A webcast of the presentation will be available through their investor website.